Since the last epidemic in 1920, it has become a matter of routine to administer subcutaneously to the mice of this cancer stock a mixed saline vaccine containing both types of mouse typhoid bacillus, in an effort to maintain the immunity of the population at a level high enough to prevent another epidemic. No further outbreak of mouse typhoid, in anything like epidemic proportions, has occurred among these mice, although there is known to be a high fecal carrier incidence of M. T. I among them, and a slight carrier incidence of M. T. II also. Furthermore, in a single experiment in which twenty-five of these mice, the unvaccinated offspring of vaccinated mothers and themselves free of fecal contamination with either type of mouse 'Lynch, C. J., J. Exp. Med., 1922, xxxvi, 15. 265 typhoid bacillus, were employed, they showed, when fed per os with M. T. II, a corrected mortality rate of only 12 per cent, as compared to a 64 per cent mortality among the controls. Practically no blood invasion occurred except in those mice which died, although among the controls blood invasion occurred at some time in 88 per cent.
Vaccination with the strain of M. T. II employed as a stock strain in our laboratory (the strain originally isolated by Amoss2) has been shown by Webster 3 to be effective in protecting mice against subsequent injection with living organisms of the homologous strain. Aside from the vaccination of the cancer stock with a mixed M. T. I and M. T. II vaccine, we had had no experience with vaccines made from Strain M. T. I except in the production of agglutinating sera in rabbits. For this reason some experiments were undertaken in the immunization of mice with vaccines made from each type of mouse typhoid bacillus, in an attempt to determine whether a heterologous as well as a homologous protection was conferred by each vaccine.
EXPERIMENTAL.
Experiment 1.--Six series of twenty-five mice each were assembled from the Rockefeller Institute breeding room, each mouse being placed in a separate battery jar. Certain of these mice had received previous vaccination, as follows:
Series A and F received subcutaneously in three successive weekly doses a monovalent M. T. I vaccine (1,000,000,000 organisms at each dose).
Series C and D received subcutaneously in three successive weekly doses a monovalent M. T. II vaccine (1,000,000,000 organisms at each dose).
The six series of mice were inoculated by means of a stomach tube 10 days after the last vaccination, as follows:
Series A (M. T. I vaccinated), 0.005 cc. of M. T. I broth culture per os.
" B (controls), 0.005
The outcome of this experiment was unexpected, as shown by mortality rates presented in Table I .
It appeared from these percentages that a definite immunity had been conferred by the M. T. II vaccine against its homologous strain, as compared with the natural immunity among the controls, but that the M. T. I vaccine, while it had apparently modified slightly the form of the mortality curve of those mice inoculated per os with the homologous strain, had afforded no more protection against this strain than was conferred by vaccination with the heterologous M. T. II, and had failed to confer any protection against the heterologous M. T. II when mice were subsequently inoculated with this organism per os. Experiment 2.-A second attempt was made to obtain a positive protection against per os inoculation of M. T. I through the previous administration of an homologous vaccine. Owing to a temporary shortage of mice, smaller numbers had to be used and it was impossible to vaccinate a parallel series with M. T. II, to repeat the experiment in cross-protection. The vaccines employed in Experiment 1 had been made by washing off with saline the 24 hour growth from several Blake bottles and heating the emulsions thus obtained to 60 0 C. in the water bath for 1 hour. In Experiment 2 a somewhat different technique was employed. The M. T. I emulsion was twice washed in saline, after removal from the Blake bottles, and was then killed by heating to 56°C. in a water bath for 1 hour. It was hoped that the lower thermal death-point would kill the bacteria without too profoundly altering the bacterial protein. As a matter of fact, even after heating for 1 hour at 56°C., the vaccine contained a very few living organisms, two or three colonies developing when 0.1 cc. of the undiluted vaccine was smeared on a green dye plate. Thymol was added to the stock vaccine for a preservative as in Experiment 1.
In performing this experiment in vaccination with M. T. I, an effort was made to answer several questions: (a) Length of time after vaccination most favorable for per os inoculation with living organisms. In an effort to determine this, mice were inoculated 7 and 14 days after their last dose of vaccine. (b) Number of doses most effective for the production of immunity. Some mice were given two doses beginning, a slight advantage over both the controls and the mice receiving larger doses of vaccine, but that this advantage was lost in the period between 15 and 18 days after inoculation. Thereafter the curves of the two vaccinated series ran an almost parallel course, with the small dose series some 10 per cent above the large dose series, and the control curve striking an almost exact average between the two, to the end of the experimental period.
The study of separate curves gives little or no evidence that one method of vaccine inoculation, as regards intervals between doses and 4'_ size of doses, was preferable to another, nor is there any clear-cut indication that a definite immunity against infection with M. T. I was conferred by any of the methods of vaccination employed. That the antigenic properties of the vaccine were not injured by heat was indicated by the fact that when injected intravenously into rabbits it was capable of calling forth the production of an excellent homologous fig. 1 ).
agglutinating serum. Mice, however, were unable to respond to the inoculations with the production of a demonstrable active immunity.
The final mortality figures for the different series are given in Table II .
The chief points of interest gained from this experiment were as follows: (a) The strain of M. T. I used in this laboratory is far more l ; toxic than the strain of M. T. II. It is not well borne, when administered subcutaneously to mice as a killed culture, even in doses as small as 25,000,000 organisms. In this experiment, each series originally included fifteen mice. At the time of their inoculation per os with living organisms, the original fifteen had diminished considerably, especially those mice that had received the larger doses, as may be seen from a survey of the numbers that finally came to inoculation (Table III) .
The large dose appears to even greater disadvantage when further deductions are made for those mice that died at 24, 48, or 72 hours after the per os inoculation, and so had to be discarded as deaths probably due to accidents associated with the inoculation (Table II) . There 
were ten such deaths among the various series of mice that had received the larger doses of vaccine (25,000,000 organisms), as against only three among the mice that had received the smaller doses (1,000,000 organisms). This may mean that the premature deaths were not wholly due to accidents of inoculation, but could be attributed, at least in part, to the lowered resistance of those animals that had received the larger doses of vaccine.
(b) This strain of M. T. I, originally isolated in our laboratory from a fatal case of mouse typhoid, is not an active antigen for the production of immunity in mice. A vaccine prepared with it, even when administered subcutaneously in two or three doses of 25,000,000 organisms each-doses large enough to prove toxic to some animalsis incapable of producing a definite immunity against subsequent per os inoculation with living cultures of M. T. I. In this respect, as well as in its toxicity, it differs from the M. T. II strain isolated in this laboratory, which possesses more readily demonstrable antigenic properties, and is capable, when used as a vaccine, of conferring a definite immunity against the homologous strain, and possibly some slight cross-protection against the M. T. I strain also. have recently described successful vaccination experiments in guinea pigs with a strain of Bacillus aertrycke (mutton) derived from a spontaneous epidemic among these animals, an organism which Webster' found to be closely related to our M. T. II strain. In the present series of experiments also, M. T. II vaccine has been found fairly effective in protecting mice against subsequent per os inoculation with the homologous strain. M. T. I vaccine, on the other hand, has failed to produce in mice, under the experimental conditions that existed here, any clearly demonstrable immunity against its homologous strain when living organisms of this strain were later administered per os. The two types of mouse typhoid bacillus appear to differ radically both in their toxic properties and in their ability to act as antigens in mice.
Under these circumstances, a question naturally arises as to the part played by the polyvalent mouse typhoid vaccine in preventing an epidemic of typhoid, due to the Type I bacillus, among the cancer stock of The Rockefeller Institute. Since fecal carriers of M. T. I are fairly numerous among these mice, they are constantly exposed to infection from this source, yet no epidemic due to M. T. I has occurred among them since 1918. Since the M. T. II outbreak in 1920, a certain level of immunity to M. T. II has been artificially maintained through vaccination of all young mice. The experiment in cross-protection indicates that some slight cross-protection may be conferred against per os inoculation of M. T. I by the administration of M. T. II vaccine, and with the relatively much smaller doses of living organisms ingested by mice under normal living conditions, with carriers present, this protection might be still more effective. It is, of course, possible that the general level of resistance of a mouse population to infection with mouse typhoid bacillus Type I might be raised through long exposure to small doses of living organisms excreted by carriers and ingested with food, even though a killed vaccine prepared from this strain is ineffective in producing immunity on subcutaneous inoculation. It seems reasonable to assume that M. T. II infection in this stock has been kept down by the homologous strain included in the vaccine administered to them, but the freedom of the animals from infection with M. T. I, in the presence of numerous carriers of this organism, can scarcely be attributed to the effects of the Type I strain included in the vaccine in view of the negative results obtained in the vaccination experiments here recorded.
SUMMARY.
A saline vaccine prepared from our stock strain of M. T. II produces in mice definite protection against the homologous strain, and perhaps some slight cross-protection against M. T. I also. Two vaccines prepared with our stock strain of M. T. I failed to produce any definite protection in mice even against the homologous strain, nor was any cross-protection afforded against M. T. II.
